Navigation Links
New molecular insight into amboebic dysentery
Date:6/14/2008

In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the treatment of amoebic dysentery, which affects 1/10th of the global population (~500 million people) and represents the second most common disease in the world.

"New drug targets are needed for amebiasis as current treatments have associated toxicities and drug resistance is a concern." said Dr. Upinder Singh, a clinician at Stanford University and co-author of the study.

E. histolytica is a single-celled intestinal parasite that infects the lower GI tract, causing amoebiasis, and can invade the intestinal wall and spread to the bloodstream, causing potentially fatal amoebic liver abscesses. The parasite is transmitted through fecally contaminated food or water, and is a major public health threat in the developing world.

Dr. Urban and colleagues uncovered new insight into the activity of E. histolytica's single rhomboid protease protein, EhROM1, which suggests that it helps the parasite evade the host's immune response. In order to escape immune detection, E. histolytica trophozoites concentrate immune system-eliciting surface proteins towards the rear of the cell and then expel them. Dr. Urban's team discovered that EhROM1 processes surface lectin proteins, and collaborators at Stanford University found that it re-localizes posteriorly during lectin shedding.

These findings suggest that EhROM1 facilitates lectin shedding and host immune system evasion by this pathogenic parasite. Dr. Urban is excited by the new findings, since "Enzymes have served as particularly successful drug targets in the past, so it's exciting to discover an ameba rhomboid enzyme with similar properties as a malaria rhomboid. We're hopeful that with additional work, we will be able to develop rhomboid inhibitors and evaluate if they could be applied as a more general anti-parasitic strategy in the future."


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
2. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
3. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
4. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
5. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
6. Research reveals molecular fingerprint of cocaine addiction
7. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
8. Study identifies molecular response of cartilage to injury
9. Molecular change may reveal risk of leukemia relapse
10. Study Details New Molecular Approach to Preventing Alzheimers
11. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology: